title: [Comparative efficacy of diclobrou for prophylaxis of NSAID-associated gastropathies in patients with osteoarthritis].
abstract: As may as 155 patients with exacerbated osteoarthrosis were examined to compare the incidence of development of erosive-and-ulcerous lesions in the gastroduodenal system under exposure to different schemes of nonsteroid-antiinflammatory drug (NAID)-therapy and over different time ranges of its administration and to assess prophylactic efficacy of the drug diclobrou (enterosoluble form of diclofenac natrium). There has been endoscopically validated usefulness of employing enterosoluble and injectable dosage forms during the first days of NAID-therapy. With signs of synovitis still in place, subsequent therapy treatments are to be administered with selective inhibitors of cyclooxigenase-2 or a simple dosage form of diclofenac should be combined with misoprostol.
authors.forename: A S
authors.initials: AS
authors.lastname: Svintsits'kyĭ
authors.forename: N I
authors.initials: NI
authors.lastname: Khomchenkova
authors.forename: O H
authors.initials: OH
authors.lastname: Puzanova
authors.forename: M F
authors.initials: MF
authors.lastname: Kushyk
authors.forename: V M
authors.initials: VM
authors.lastname: Bohomaz
authors.forename: Z O
authors.initials: ZO
authors.lastname: Dubovenko
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004008:Diclofenac / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004304:Dosage Forms; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015994:Incidence; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D016595:Misoprostol / Q000627:therapeutic use; D010003:Osteoarthritis / Q000188:drug therapy*; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D012995:Solubility
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000897:Anti-Ulcer Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004304:Dosage Forms; D007527:Isoenzymes; D008565:Membrane Proteins; D016595:Misoprostol; D004008:Diclofenac; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases
vernacular_title: Porivnial'na efektyvnist' dyklobriu dlia profilaktyky NPZZ-hastropatiï u khvorykh na osteoartroz.